Price target
146.460.00 0.00%
The 25 analysts offering 1 year price forecasts for NB3 have a max estimate of — and a min estimate of —.
Analyst rating
Based on 28 analysts giving stock ratings to NB3 in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
NB3 EPS for the last quarter is 0.38 CHF despite the estimation of 0.99 CHF. In the next quarter EPS is expected to reach 1.04 CHF. Track more of NEUROCRINE BIOSCIE financials and stay on top of what is up with the company.
In the next quarter NEUROCRINE BIOSCIE revenue is expected to reach 499.64 M CHF. Check out NEUROCRINE BIOSCIE revenue and earnings and make informed decisions.
According to analysts, NB3 price target is 146.46 CHF with a max estimate of 197.25 CHF and a min estimate of 101.37 CHF. Check if this forecast comes true in a year, meanwhile watch NEUROCRINE BIOSCIE stock price chart and keep track of the current situation with NB3 news and stock market news.
We've gathered opinions of 28 analysts rating NB3 stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.